Drug Profile


Alternative Names: SM 9527; Solclot

Latest Information Update: 12 Jun 1996

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Baxter International; Wyeth
  • Developer Baxter International; GlaxoSmithKline; Sumitomo Pharmaceuticals; Wyeth
  • Class Plasminogen activator enzymes; Thrombolytics
  • Mechanism of Action Plasminogen activators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.


Highest Development Phases

  • Market Withdrawal Myocardial infarction

Most Recent Events

  • 12 Jun 1996 Discontinued-Clinical for Myocardial infarction in Eastern Europe (Unknown route)
  • 12 Jun 1996 Discontinued-I for Myocardial infarction in United Kingdom (Unknown route)
  • 12 Jun 1996 Discontinued-II for Myocardial infarction in Canada (Unknown route)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top